nach oben

Drugs

Erschienen in:

01.12.2000 | Review Article

ZD1839 (‘Iressa’)^1,2 as an Anticancer Agent

verfasst von: Dr José Baselga, Steven D. Averbuch

Erschienen in: Drugs | Sonderheft 1/2000

Einloggen, um Zugang zu erhalten

Abstract

ZD1839 (‘lressa’)^1,2 is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversible growth inhibition and growth delay in a wide range of tumour cell lines and human tumour xenografts. Moreover, this activity was enhanced when ZD1839 was coadministered with cytotoxic agents. Preliminary results from phase I trials in patients with advanced disease and a wide variety of tumour types suggest that ZD1839 has an acceptable tolerability profile and promising clinical efficacy, particularly in non-small cell lung cancer (NSCLC). ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC. In addition, further trials are ongoing or planned in a number of other tumour types.

‘Iressa’ is a trademark of the AstraZeneca group of companies.

Use of a trade name is for product identification purposes only, and does not imply endorsement.

Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–67PubMedCrossRef

Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994; 19: 459–63PubMedCrossRef

Favoni RE, de Cupis A. The role of polypeptide growth factors in human carcinomas; new targets for a novel pharmacological approach. Pharmacol Rev 2000; 52: 179–206PubMed

Aaronson SA. Growth factors and cancer. Science 1991; 254: 1146–53PubMedCrossRef

Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637–43PubMedCrossRef

Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82 (2–3): 241–50CrossRef

Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232PubMedCrossRef

Voldborg BR, Damstrup L, Spang-Thomsen M, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8: 1197–206PubMedCrossRef

Batra SK, Castelino Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995; 6(10): 1251–9PubMed

10.

Chu CT, Everiss KD, Wikstrand CJ, et al. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997; 324 (Pt 3): 855–61PubMed

11.

Pawson T. Tyrosine kinases and their interactions with signalling proteins. Curr Opin Genet Dev 1992; 2: 4–12PubMedCrossRef

12.

Woodburn J, Kendrew J, Fennell M, et al. ZD1839 (‘Iressa’) a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition [abstract no. 2552]. Presented at the American Association of Cancer Research: 2000 Apr 1–5; San Francisco, USA. Proc Amer Assoc Cancer Res 2000; 41

13.

Woodburn JR, Barker AJ, Wakeling AE, et al. 6-amino-4 (3-methyl-phenylamino)-quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumour xenografts. Proc Am Assoc Cancer Res 1996; 36: 390–1

14.

Budillon A, Di Gennaro E, Barbarino M, et al. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27^KiP1 inducing G1 arrest and enhancing the antitumor effect of Interferon a [abstract no. 4910]. Presented at the American Association of Cancer Research: 2000 Apr 1–5; San Francisco, USA. Proc Amer Assoc Cancer Res 2000; 41

15.

Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27^Kip1-CdK2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000: 20: 3210–23PubMedCrossRef

16.

Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053–63PubMed

17.

Cullinane C, Kleinschmidt M, Webster LK. Antitumour activity of ZD1839 (‘Iressa’) in combination with cisplatin in NIH3T3 cells expressing human epidermal growth factor receptor [abstract no. 3073]. Presented at the American Association of Cancer Research: 2000 Apr 1–5; San Francisco, USA. Proc Amer Assoc Cancer Res 2000; 41

18.

Sirotnak FM, Zakowsky MF, Miller VA, et al. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa™), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR [abstractno. 3076]. Presented at the American Association of Cancer Research: 2000 Apr 1–5; San Francisco, USA. Proc Amer Assoc Cancer Res 2000; 41

19.

Chan KC, Knox F, Woodburn JR, et al. EGFR tyrosine kinase inhibition decreases epithelial proliferation in DCIS of the breast, whereas c-erbB2 blockade does not [abstract no. 3074]. Presented at the American Association of Cancer Research: 2000 Apr 1–5; San Francisco, USA. Proc Amer Assoc Cancer Res 2000; 41

20.

Kelly HC, Laight A, Morris CQ, et al. Phase I data of ZD 1839-an oral epidermal growth factor receptor tyrosine kinase inhibitor [abstract no 419]. Ann Oncol 1998; 2: 109

21.

Kelly HC, Ferry D, Hammond L, et al. ZD1839 (‘Iressa’), an oral EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor): pharmacokinetics in a Phase I study of patients with advanced cancer [abstract no. 3896]. Presented at the American Association of Cancer Research: 2000 Apr 1–5; San Francisco, USA. Proc Amer Assoc Cancer Res 2000; 41

22.

Goss G, Hirte H, Batist G, et al. NCIC CTG IND.122: a two-part Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 [abstract no 880]. Proc Am Soc Clin Oncol 2000; 19: 225a

23.

Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability [abstract no 686]. Proc Am Soc Clin Oncol 2000; 19: 177a

24.

Nakagawa K, Yamamoto N, Kudoh S, et al. A Phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours [abstract no 711]. Proc Am Soc Clin Oncol 2000; 19: 183a

25.

Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a Phase I study [abstract no 5E]. Proc Am Soc Clin Oncol 2000; 19: 3a

26.

Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 1999; 26 (1 Suppl. 4): 3–11PubMed

27.

Johnson DH. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience. Chest 2000; 117 Suppl. 1: 133–7CrossRef

Titel: ZD1839 (‘Iressa’)1,2 as an Anticancer Agent
verfasst von: Dr José Baselga
Steven D. Averbuch
Publikationsdatum: 01.12.2000
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe Sonderheft 1/2000
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200060001-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2000

Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents

Questions and Answers